There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biogen (BIIB – Research Report), Applied DNA Sciences (APDN – Research Report) and Cidara Therapeutics (CDTX – Research Report) with bullish sentiments.
Biogen (BIIB)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Biogen, with a price target of $325.00. The company’s shares closed last Wednesday at $261.22.
According to TipRanks.com, Fein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biogen with a $330.94 average price target, which is a 24.4% upside from current levels. In a report issued on March 12, SVB Securities also maintained a Buy rating on the stock with a $310.00 price target.
See the top stocks recommended by analysts >>
Applied DNA Sciences (APDN)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Applied DNA Sciences today and set a price target of $5.00. The company’s shares closed last Wednesday at $1.15, close to its 52-week low of $0.62.
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Applied DNA Sciences with a $4.00 average price target.
Cidara Therapeutics (CDTX)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Cidara Therapeutics today and set a price target of $6.00. The company’s shares closed last Wednesday at $1.90.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Cidara Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $4.67, a 124.5% upside from current levels. In a report issued on March 8, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIIB:
- Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
- FDA Peripheral/Central Nervous System Drugs Advisory Committee holds meeting
- FDA briefing docs suggest FDA in favor of Biogen’s tofersen, says BofA
- FDA posts briefing document for advisors’ review of Biogen’s ALS drug
- Stifel trims Biogen target, but has more confidence lecanemab ‘best-in-class’
